Form 13-F position report

REGENERON PHARMACEUTICALS

Reported by Sarissa Capital Management LP

REGN CUSIP 75886F107 Manager CIK 0001577524

Reported 4,190 shares, unchanged from the prior quarter.

Reported value 21.6%; share count 0.0% vs. the prior quarter.

Unchanged
% of reported 13F value 2.07% This manager · Q3 2026
Shares 4,190 Quarter-end amount reported
Reported value $3,177,151 Fair value at quarter end
Consecutive quarters held 5 Through Q3 2026

Reported position value by quarter

Reported position value by quarter

Each bar is a Form 13-F quarter-end snapshot. It does not show trades made within the quarter.

Reported position value by quarter
Date Holding Value
2025-09-30 2355911
2025-12-31 3234135
2026-03-31 3237362
2026-06-30 2612633
2026-09-30 3177151

Quarterly position history

How this manager's reported quarter-end position changed over time.

5 quarters
Quarterly reported position history for REGENERON PHARMACEUTICALS held by Sarissa Capital Management LP.
Quarter Activity Shares Change % of reported 13F Reported value Filed Source filing
Q3 2026 Unchanged 4,190 0 (0.0%) 2.07% $3,177,151 2026-11-16
Q2 2026 Unchanged 4,190 0 (0.0%) 1.47% $2,612,633 2026-08-14
Q1 2026 Unchanged 4,190 0 (0.0%) 2.05% $3,237,362 2026-05-15
Q4 2025 Unchanged 4,190 0 (0.0%) 1.45% $3,234,135 2026-02-17
Q3 2025 New 4,190 +4,190 (0.0%) 1.31% $2,355,911 2025-11-14

Who else reported the position

1517 managers reported REGENERON PHARMACEUTICALS for Q3 2026.

Managers reporting REGENERON PHARMACEUTICALS in Q3 2026.
Manager Activity Shares Change % of reported 13F Reported value Tenure
BlackRock Inc Reduced 8,849,583 -263,923 0.1% $6,710,372,953 9 qtrs
VANGUARD CAPITAL MANAGEMENT LLC Reduced 6,522,346 -107,413 0.1% $4,945,699,301 3 qtrs
STATE STREET CORPORATION Added 4,881,362 +46,674 0.11% $3,701,390,364 54 qtrs
Dodge & Cox Reduced 4,774,489 -96,648 1.94% $3,620,351,774 20 qtrs
Invesco Ltd Reduced 3,721,270 -219,395 0.22% $2,821,727,063 54 qtrs
FRANKLIN RESOURCES INC Added 2,950,805 +178,966 0.58% $2,746,225,687 54 qtrs
JPMorgan Chase & Co Reduced 3,307,392 -466,807 0.13% $2,482,231,986 54 qtrs
VANGUARD PORTFOLIO MANAGEMENT LLC Reduced 3,111,677 -63,636 0.11% $2,359,491,319 3 qtrs
GEODE CAPITAL MANAGEMENT LLC Added 2,632,826 +7,016 0.1% $1,992,068,413 54 qtrs
Nuveen LLC Reduced 1,955,949 -64,025 0.35% $1,483,137,489 7 qtrs
Premium adds each manager's conviction percentile across reporting peers.
Filing details and methodology As reported
Report period
September 30, 2026
Filed
November 16, 2026
Filing type
13F-HR
Position type
COM

Voting authority reported

Sole
4,190
Shared
0
None
0

“None” means the manager reported no voting authority for those shares on non-routine matters. It does not disclose why and is not evidence of securities lending.

Form 13-F is a delayed quarter-end snapshot of disclosed long Section 13(f) securities. It can be filed up to 45 days after quarter end, excludes short positions and most non-U.S. securities, and does not reveal intra-quarter trading. For options, reported shares and value describe the underlying-share exposure; strike, expiry, premium, and written positions are not disclosed.